FURACIN
LOE ApproachingNDATOPICALOINTMENT
Approved
Oct 1945
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FURACIN is a topical ointment small molecule approved in 1945 for wound and burn care. The product's specific mechanism of action and exact indications are not documented in available data. It remains a legacy antibiotic-class topical agent used in clinical settings for tissue repair.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal current career growth signals; teams are likely consolidating or transitioning to newer therapies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FURACIN represents a late-stage legacy product with zero linked job openings and declining strategic importance. Career growth is limited; roles focus on product stewardship, supply continuity, and eventual transition planning rather than innovation or market expansion.
Brand Manager (legacy)Sales Representative
Worked on FURACIN at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.